procollagen iii peptide  (srl inc)

Journal: Critical Care Explorations

Article Title: Immunocompromised Children With Acute Respiratory Distress Syndrome Possess a Distinct Circulating Inflammatory Profile

doi: 10.1097/CCE.0000000000000844

Figure Lengend Snippet: Biomarker Levels (Median and Interquartile Ranges) of Subjects Stratified According to Neutropenia (Absolute Neutrophil Count < 1,000)

Article Snippet: Candidate biomarkers were chosen based on prior literature: olfactomedin 4 (OLFM4), granzyme B, heat shock protein 70 (HSP70), interleukin (IL)-1α, IL-8, C-C motif chemokine ligand (CCL) 3/macrophage inflammatory protein (MIP)-1α, MIP-1β, matrix metalloproteinase 8 (MMP8), CCL7, CCL22, IL-6, soluble tumor necrosis factor receptor 1 (sTNFR1), tumor necrosis factor α (TNFα), nucleosomes (Sigma-Aldrich, St. Louis, MO), procollagen type III N-terminal peptide (P3NP; Abbexa, Cambridge, United Kingdom), surfactant protein D (SPD), angiopoietin-2 (ANG2), and soluble receptor for advanced glycation end-products (sRAGE).

Techniques: Biomarker Assay

Journal: Critical Care Explorations

Article Title: Immunocompromised Children With Acute Respiratory Distress Syndrome Possess a Distinct Circulating Inflammatory Profile

doi: 10.1097/CCE.0000000000000844

Figure Lengend Snippet: Selected unadjusted biomarker levels compared between immunocompetent (no immunocompromising condition [ICC]), ICC without stem cell transplant (SCT) (ICC no SCT), and ICC with SCT (ICC + SCT) subjects. Biomarkers were log-transformed and compared using analysis of variance, with post hoc Bonferroni corrections displayed (* p < 0.05; ** p < 0.01; *** p < 0.001). Data are back-transformed and presented as medians and interquartile ranges. ANG2 = angiopoietin-2, CCL22 = C-C motif chemokine ligand 22, IL-8 = interleukin-8, P3NP = procollagen type III N-terminal peptide, SPD = surfactant protein D, sTNFR1 = soluble tumor necrosis factor receptor 1.

Article Snippet: Candidate biomarkers were chosen based on prior literature: olfactomedin 4 (OLFM4), granzyme B, heat shock protein 70 (HSP70), interleukin (IL)-1α, IL-8, C-C motif chemokine ligand (CCL) 3/macrophage inflammatory protein (MIP)-1α, MIP-1β, matrix metalloproteinase 8 (MMP8), CCL7, CCL22, IL-6, soluble tumor necrosis factor receptor 1 (sTNFR1), tumor necrosis factor α (TNFα), nucleosomes (Sigma-Aldrich, St. Louis, MO), procollagen type III N-terminal peptide (P3NP; Abbexa, Cambridge, United Kingdom), surfactant protein D (SPD), angiopoietin-2 (ANG2), and soluble receptor for advanced glycation end-products (sRAGE).

Techniques: Biomarker Assay, Transformation Assay

Journal: Critical Care Explorations

Article Title: Immunocompromised Children With Acute Respiratory Distress Syndrome Possess a Distinct Circulating Inflammatory Profile

doi: 10.1097/CCE.0000000000000844

Figure Lengend Snippet: Selected biomarker levels adjusted for severity of illness and acute respiratory distress syndrome etiology, compared between immunocompetent (no immunocompromising condition [ICC]), ICC without stem cell transplant (SCT) (ICC no SCT), and ICC with SCT (ICC + SCT) subjects. Biomarkers were log-transformed for regression, predicted values computed, and compared between groups using analysis of variance, with post hoc Bonferroni corrections displayed (* p < 0.05; ** p < 0.01; *** p < 0.001). Data are presented as medians and interquartile ranges. ANG2 = angiopoietin-2, CCL22 = C-C motif chemokine ligand 22, IL-8 = interleukin-8, P3NP = procollagen type III N-terminal peptide, SPD = surfactant protein D, sTNFR1 = soluble tumor necrosis factor receptor 1.

Article Snippet: Candidate biomarkers were chosen based on prior literature: olfactomedin 4 (OLFM4), granzyme B, heat shock protein 70 (HSP70), interleukin (IL)-1α, IL-8, C-C motif chemokine ligand (CCL) 3/macrophage inflammatory protein (MIP)-1α, MIP-1β, matrix metalloproteinase 8 (MMP8), CCL7, CCL22, IL-6, soluble tumor necrosis factor receptor 1 (sTNFR1), tumor necrosis factor α (TNFα), nucleosomes (Sigma-Aldrich, St. Louis, MO), procollagen type III N-terminal peptide (P3NP; Abbexa, Cambridge, United Kingdom), surfactant protein D (SPD), angiopoietin-2 (ANG2), and soluble receptor for advanced glycation end-products (sRAGE).

Techniques: Biomarker Assay, Transformation Assay

Journal: Frontiers in physiology

Article Title: Non-alcoholic fatty liver disease-A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease.

doi: 10.3389/fphys.2022.963513

Figure Lengend Snippet: FIGURE 2 Serum levels for biomarkers of fibrosis. (A) PIIINP levels were significantly higher in the NAFLD/NASH and ALD groups compared to simple steatosis and control subjects. (B) ST2/IL-33R was significantly higher in the NAFLD/NASH and ALD groups compared to simple steatosis and control subjects. Stars of significance; *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: Five biomarkers were evaluated using ELISAs, according to manufacturer’s instructions: Midkine (LyraMid, Sydney, Australia), mean detectable dose (MDD) 8 pg/ml, Fatty AcidBinding Protein-1 (FABP-1) (Abcam, Cambridge, United Kingdom), MDD 1.0 ng/ml, Procollagen-III-peptide (PIIINP) (Cusabio, Houston, US), MDD 0.078 ng/ml, Apolipoprotein F (ApoF) (LSBio, Seattle, United Kingdom), MDD 0.41 ng/ml, and Suppression of Tumorigenicity (ST2/IL33R) (R&D Systems, Abingdon Science Park, United Kingdom), MDD 5.1 pg/ml.

Techniques: Control